Next Article in Journal
Insight into Rapid DNA-Specific Identification of Animal Origin Based on FTIR Analysis: A Case Study
Next Article in Special Issue
Protective Effect of Phenolic Compounds Isolated from Mugwort (Artemisia argyi) against Contrast-Induced Apoptosis in Kidney Epithelium Cell Line LLC-PK1
Previous Article in Journal
Phytotoxic Compounds Isolated from Leaves of the Invasive Weed Xanthium spinosum
Previous Article in Special Issue
Neuroprotective Role of Phytochemicals
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 23
Issue 11
10.3390/molecules23112841
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

A Systems-Level Analysis of Mechanisms of Platycodon grandiflorum Based on A Network Pharmacological Approach

by
Musun Park
1,†,
Sa-Yoon Park
1,†,
Hae-Jeung Lee
2,* and
Chang-Eop Kim
1,*
1
Department of Physiology, College of Korean Medicine, Gachon University, Seongnam 13120, Korea
2
Department of Food and Nutrition, College of BioNano Technology, Gachon University, Seongnam 13120, Korea
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this work.
Molecules 2018, 23(11), 2841; https://doi.org/10.3390/molecules23112841
Submission received: 27 September 2018 / Revised: 23 October 2018 / Accepted: 29 October 2018 / Published: 1 November 2018
(This article belongs to the Special Issue The Potential Use of Herbal Medicinal Products in Chronic Disorders)
Browse Figures
Versions Notes

Abstract

:
Platycodon grandiflorum (PG) is widely used in Asia for its various beneficial effects. Although many studies were conducted to understand the molecular mechanisms of PG, it is still unclear how the combinations of multiple ingredients work together to exert its therapeutic effects. The aim of the present study was to provide a comprehensive review of the systems-level mechanisms of PG by adopting network pharmacological analysis. We constructed a compound–target–disease network for PG using experimentally validated and machine-leaning-based prediction results. Each target of the network was analyzed based on previously known pharmacological activities of PG. Gene ontology analysis revealed that the majority of targets were related to cellular and metabolic processes, responses to stimuli, and biological regulation. In pathway enrichment analyses of targets, the terms related to cancer showed the most significant enrichment and formed distinct clusters. Degree matrix analysis for target–disease associations of PG suggested the therapeutic potential of PG in various cancers including hepatocellular carcinoma, gastric cancer, prostate cancer, small-cell lung cancer, and renal cell carcinoma. We expect that network pharmacological approaches will provide an understanding of the systems-level mechanisms of medicinal herbs and further develop their therapeutic potentials.

1. Introduction

Platycodon grandiflorum (PG), known as Kilkyung (in Korea), Jiegeng (in China), or Kikyo (in Japan), is widely used worldwide for its therapeutic effects on cough, phlegm, sore throat, and so on. So far, many studies focused on the biological effects of PG, such as anti-inflammatory [1,2,3], anti-cancer [4,5], anti-oxidative [6,7], and anti-obesogenic properties [8]. In particular, a number of studies investigated the efficacy of platycodin D, the main active component of PG. Platycodin D was found to have diverse pharmacological effects, such as inducing apoptosis [9,10,11,12,13], anti-obesity [14,15], and anti-inflammatory effects [16,17,18], increasing airway mucin release [19,20], and protection against hepatotoxicity [21,22]. However, PG contains various ingredients in addition to platycodin D, and many of the ingredients may work together to exert the therapeutic effects of PG.
Despite many studies trying to understand the molecular mechanisms of PG, it is still unclear how the combinations of multiple ingredients work together to exert its therapeutic effects. Since most diseases are caused by an interplay of multiple molecular components [23], it is necessary to decipher the systems-level mechanisms of PG to understand and further develop its therapeutic potential.
Network pharmacology is a novel approach for investigating the systems-level mechanisms of drugs [24]. It integrates multiple sources of information and adopts computational methods such as bioinformatics and network analysis, as well as experimental approaches. Recently, network pharmacological approaches were employed to investigate the systems-level mechanisms of herbs or herbal formulae, highlighting the potential of traditional herbal medicine in “multi-compound, multi-target” therapeutics [25,26,27,28,29].
So far, there are several studies reviewing the therapeutic mechanisms of PG systemically based on individual experimental results; however, there were no attempts to apply network pharmacological analysis to decipher the systems-level mechanisms of PG. In this review, we attempt to provide comprehensive insight into the systems-level mechanisms of PG by adopting network pharmacological analysis. Firstly, we briefly introduce the chemical constituents that have a high possibility of being active compounds. Next, we constructed a compound–target–disease network using compound–target interaction data from the Traditional Chinese Medicine Systems Pharmacology database (TCMSP, http://lsp.nwu.edu.cn/tcmsp.php) [30]. In order to review the major targets of PG, the Uniprot database (https://www.uniprot.org/) was employed, and, to survey the pathways of selected targets, the Protein Analysis Through Evolutionary Relationships (PANTHER, http://www.pantherdb.org/) [31,32] classification system, Enrichr method (http://amp.pharm.mssm.edu/Enrichr/) [33,34], and clustergram method were applied [35]. Finally, absolute and relative degree matrices were constructed from a network of PG to investigate related diseases (Figure 1).

2. Compound Analysis

Among the compounds contained in the herb, not all compounds have drug characteristics. To search for compounds that have potential as a drug, we applied oral bioavailability (OB) and drug-likeness (DL) data to the compound the filtering process. [36]. OB is calculated based on permeability (P)-glycoprotein and cytochrome P450, which affect drug absorption and metabolism [37]. Meanwhile, DL is derived using Lipinski’s rule of five and Tanimoto coefficients [38]. To extract candidate compounds from PG, the thresholds of OB and DL were set to ≥30 (OB) and ≥0.18 (DL) and applied for filtering. Compound information was extracted from the TCMSP database [30]. The candidate compounds turned out to be as follows: acacetin, luteolin, cis-dihydroquercetin, spinasterol, robinin, 2-O-methyl-3-O-β-d-glucopyranosyl platycogenate, and dimethyl 2-O-methyl-3-O-α-d-glucopyranosyl platycogenate A. Among them, compounds with no interacting target were excluded, resulting in three flavonoids (acacetin, luteolin, cis-dihydroquercetin) and one steroid (spinasterol) (Figure 2a).
Acacetin was reported to inhibit the proliferation of cancer cells by blocking cell-cycle progression and inducing apoptosis. For example, it was demonstrated to obstruct the proliferation of cancer cells from liver, lung, prostate, and breast tumors [39,40,41,42]. Dihydroquercetin was shown to have neuroprotective and hepatoprotective activity through antioxidant effects [43,44]. Luteolin was found to promote antioxidant activity [45,46], lipolysis [47], and anti-angiogenic activity [48]. Spinasterol was investigated for anti-carcinogenic [49], anti-tumor [50], and anti-nociceptive effects [51].
It is worthy of note that there can be other potential therapeutic compounds of PG in addition to the compounds we suggested based on the TCMSP database and filtering process. For example, platycodin D is the most frequently reported active compound among PG compounds [52,53] although it showed OB and DL values below the threshold (7.60 and 0.01, respectively) (Figure 2b). Platycodin D was reported to have various pharmacological effects, such as inducing apoptosis [9,10,11,12,13], as well as anti-obesity [14,15] and anti-inflammatory [16,17,18] properties, increasing airway mucin release [19,20], and protection against hepatotoxicity [21,22].

3. Construction of PG Compound–Target–Disease (CTD) Network

In order to predict the systemic therapeutic effects of PG, we constructed a CTD network comprising three types of nodes (compounds, targets, and diseases) and two types of edges (between compounds and targets, and between targets and diseases; CT and TD interactions, respectively). CT and TD interaction information was extracted from TCMSP. CT interaction data include not only experimentally validated interactions, but also predicted interactions based on machine learning (ML) methods such as support vector machines and random forest algorithms. The performance of this ML-based method was proven to be reliable [54].
The degree of each node was defined by the number of connections that the node has. Specifically, target degree was defined as the number of connections each target has to compounds, and disease degree was defined as the number of connections each disease has to targets. To explore as many potential targets and diseases of PG as possible, the thresholds of OB and DL were set to 0. Instead, we only included targets and diseases with more than three degrees in further analysis. Cytoscape 3.6.1 (http://www.cytoscape.org/) [55] was used to visualize the constructed network (Figure 3).
The CTD network constructed for PG contained 33 compounds, 40 targets, and 28 diseases. Five targets with the most degrees among the 40 targets were as follows: trypsin-1, dipeptidyl peptidase IV, estrogen receptor, prostaglandin G/H synthase 2, and prostaglandin G/H synthase 1; the top five diseases that were most relevant to PG were as follows: unspecific cancer, breast cancer, pancreatic cancer, Alzheimer’s disease, and prostate cancer.

4. Target Analysis

Since presenting only the name of the target has limitations in providing an understanding of the therapeutic effects of PG, we queried the top 10 biological functions of each target in Uniprot, a target annotation information database. Since many of the CT interactions in the network were based on the results of ML prediction without experimental validation, there is the possibility of spurious interactions in the network. Therefore, we mainly focused on targets with high numbers of degrees (top 10 targets) for target analysis. Among many target annotations in Uniprot, to find the pharmacological functions of PG, 12 pharmacological activities of PG were pre-selected based on two review papers [56,57], i.e., apophlegmatic and antitussive, immune, anti-inflammatory, anti-oxidant, anti-tumor and anti-cancer, anti-diabetic, anti-obesity, anti-allergic, anti-microbial, cardiovascular, hepatoprotective, and neuroprotective activities. The pharmacological activities of each target were retrieved from the annotation information of Uniprot and matched with the pharmacological activities of PG (Table 1).
Among the top 10 targets, DPP4 is known as a gene involved in T-cell immune activation, and has a biological process of insulin secretion, as well as locomotor and psychomotor behavior. ERS1 and AR are involved in gene expression control, which affect cell proliferation and differentiation of the target tissue. In particular, ERS1 is known to act on cancer, tumor, and inflammation by controlling phosphatidylinositol 3-kinase (PI3K)/Protein Kinase B (Akt) signaling associated with cell abnormal proliferation [58], and AR is known to be associated with prostate cancer [59]. PTGS2, better known as COX2, is involved in prostanoid synthesis. This gene was reported to cause inflammatory responses and phenotypic changes, resistance to apoptosis, tumor angiogenesis, and cancer [60,61,62]. NOS2 is a gene that produces nitric oxides (NOs), mediating tumoricidal and bactericidal actions in macrophages [63]. This gene is also closely related to the inflammatory response because it is involved in prostaglandin secretion [62]. CA2 is known as the target of breast cancer and glaucoma treatment drugs [64]. CA2 is also related to osteopetrosis because it plays an important role in bone resorption and osteoclast differentiation [65].

5. Pathway Analysis

Next, we performed pathway analysis using predicted targets of PG. Pathway analysis aims to provide insight into the biological processes involved in the predicted targets. Firstly, to capture the related biological functions of PG, every target of the CT network was assigned to biological processes using the “PANTHER GO-Slim Biological Process” feature of the PANTHER database [31].
As a result, 112 targets were assigned to 261 biological processes. Biological processes were classified into 11 categories as follows: cellular process, metabolic process, response to stimulus, biological regulation, multicellular organismal process, developmental process, localization, cellular component organization or biogenesis, immune system process, locomotion, and reproduction (Figure 4)
We also applied gene set enrichment analysis (GSEA) [66] to investigate target-related pathways. The pathway information of the Kyoto Encyclopedia of Genes and Genomes (KEGG) 2016 database (https://www.kegg.jp/) [67] was used for the enrichment analysis. The top 10 enriched terms were ranked in descending order as follows: pathways in cancer, PI3K/Akt signaling pathway, hypoxia-inducible factor 1 (HIF-1) signaling pathway, prostate cancer, advanced glycation end products (AGE)/receptor for advanced glycation end products (RAGE) signaling pathway in diabetic complications, hepatitis B, proteoglycans in cancer, glioma, estrogen signaling pathway, and small-cell lung cancer. These enriched terms were visualized as a bar graph using a combined score and as a network based on the gene content similarity among the enriched terms (Figure 5) [33,34]. The network of pathways provides information on how the diverse pathways are related in terms of the target genes of PG. We found that PG mainly acts on pathways related to cancers, and non-cancer pathways such as hepatitis B, AGE/RAGE, and glioma, which share target genes in common with various cancer-related pathways.
To show how the pathways share target genes in common in more detail, we constructed a clustergram of pathways and genes. Only pathways with combined scores greater than 20 were included in the clustergram (Figure 6). To define clusters, we cut the dendrogram at the fifth level, resulting in nine clusters (Table 2). We found that many of the clusters were cancer pathways or closely related to cancers (clusters 1, 2, 3, 4, 8, and 9). These findings are consistent with many previous studies of PG. For example, PG was reported to inhibit proliferation of HT-29 colon cancer cells by inducing apoptosis via both caspase-dependent and -independent pathways [5]. Also, Shin et al. reported the effects of platycodin D on the production of reactive oxygen species (ROS) and showed the association of these effects with apoptotic tumor cell death [68]. PI3K-Akt signaling pathway which stimulates cell growth and cell cycle progression, is closely related to oncogenesis, and has been reported as a major cancer control pathway of PG [69,70]. Also, several studies have reported that PG stimulates NO and TNF-α release and is able to upregulate iNOS and TNF-α expression for anti-tumor activity [71,72].

6. Disease Analysis

Finally, we analyzed the therapeutic effects of PG on diseases. Potential target diseases of PG were analyzed based on the target–disease information from TCMSP, which extracted information from PharmGKB (https://www.pharmgkb.org/) [73] and the Therapeutic Targets Database (http://bidd.nus.edu.sg/BIDD-Databases/TTD/TTD.asp) [74]. At first, disease degrees were calculated for all diseases in TCMSP by counting the number of interactions with targets in the constructed CTD network of PG (Figure 7a and Table 3). Since the results are affected by the selection of thresholds for OB and DL, the degrees of diseases were calculated across a wide range of thresholds, resulting in a degree matrix of diseases. In the matrix, only diseases whose average disease degree was >3 were displayed. Unspecific cancer shows the highest degree, followed by cancer-related diseases such as breast cancer, pancreatic cancer, and prostate cancer. Among non-cancer diseases, Alzheimer’s disease shows the highest degree.
The high proportion of cancer diseases in our results raised concerns that the results could be biased to specific diseases that have many related genes in the database (target genes are not evenly distributed for diseases). To avoid this bias, we calculated the relative degrees by dividing each degree by the maximum degree of the corresponding disease. The relative degree of a disease shows a comparative advantage of PG for various diseases by controlling for the frequency of the disease in the database (Figure 7b and Table 4). The results of the relative degree analysis were not identical with those of the absolute degree analysis, but the overall trend of a high proportion of cancer diseases was found again. Major diseases targeted by PG according to relative degrees are as follows: hepatocellular carcinoma, gastric cancer, prostate cancer, small-cell lung cancer, and renal cell carcinoma. Our network pharmacological analysis of target diseases of PG concurs with many previous studies on PG. The anti-cancer effect of PG was actively verified on various cancers such as hepatocellular carcinoma [11,12], lung cancer [4,10], breast cancer [13,75], colon cancer [5], and leukemia [68]. In addition, several studies described the beneficial effects of PG on various diseases such as anti-obesity [76,77] and neuroprotective [78] effects, and immune system activation [79,80].

7. Concluding Remarks and Future Directions

PG contains various ingredients, as well as platycosides (e.g., platycodin D), and these components could interact with multiple targets and pathways simultaneously in a complex manner to exert PG’s therapeutic effects. However, it is a challenging task to understand the complex mechanisms of action of PG at a systems level via conventional approaches based on reductive analysis. In the present study, we attempted to review the systems-level mechanisms of PG by applying network pharmacological methods, such as CTD network construction, target analysis, pathway analysis, and disease analysis using bioinformatics tools and databases. Our analysis revealed candidate targets of PG and target-related pathways which take the simultaneous actions of multiple compounds on multiple targets into account. We can also suggest potential target diseases of PG from this analysis, providing insight into PG’s therapeutic potential. We employed various analytical approaches to give reliable information at multiple levels and showed consistent results throughout the analysis. Furthermore, we tried avoiding publication bias that can occur when using bioinformatics databases in disease analysis, by considering the relative degree of diseases [25].
Although our network pharmacology-based review of systems-level mechanisms of PG is encouraging, a limitation should also be noted. Currently, there are several different approaches to each network pharmacological analysis step, such as the predictions of OB, DL, and drug–target interactions [36], and there is no consensus about which approaches are more appropriate for understanding the systems-level mechanisms of herbs with multiple components. Since the results of analysis are dependent on adopted methodologies, future studies are needed to optimize each step of the analysis by combining experimental validation data. It will also be necessary to incorporate multi-scale models of diseases and drugs based on systems-level experiments such as gene expression profiling, because they can provide more downstream results of complex interactions between multiple target genes [81,82]. In spite of this limitation, however, we found that our prediction-based results were generally consistent with previous research on pathways and diseases treated with PG extracts. Furthermore, we can suggest more comprehensive mechanisms of therapeutic effects of PG in terms of target proteins, pathways, and diseases than manual reviews of the literature. We expect that the review of systems-level mechanisms of herbs via network pharmacology will be a valuable approach for understanding and developing the therapeutic potential of herbs.

Author Contributions

C.-E.K. and H.-J.L. planned and designed the study. M.P. performed the analysis, and M.P. and S.-Y.P. interpreted the results. M.P. and S.-Y.P. wrote the manuscript with support from C.-E.K. and H.-J.L.

Funding

This work was carried out with the support of “Cooperative Research Program for Agriculture Science and Technology Development (Project No. PJ0138102018)”, Rural Development Administration, Republic of Korea.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Choi, J.H.; Hwang, Y.P.; Lee, H.S.; Jeong, H.G. Inhibitory effect of Platycodi Radix on ovalbumin-induced airway inflammation in a murine model of asthma. Food Chem. Toxicol. 2009, 47, 1272–1279. [Google Scholar] [CrossRef] [PubMed]
  2. Jang, K.J.; Kim, H.K.; Han, M.H.; Oh, Y.N.; Yoon, H.M.; Chung, Y.H.; Kim, G.Y.; Hwang, H.J.; Kim, B.W.; Choi, Y.H. Anti-inflammatory effects of saponins derived from the roots of Platycodon grandiflorus in lipopolysaccharidestimulated BV2 microglial cells. Int. J. Mol. Med. 2013, 31, 1357–1366. [Google Scholar] [CrossRef] [PubMed]
  3. Ahn, K.S.; Noh, E.J.; Zhao, H.L.; Jung, S.H.; Kang, S.S.; Kim, Y.S. Inhibition of inducible nitric oxide synthase and cyclooxygenase II by Platycodon grandiflorum saponins via suppression of nuclear factor-kappaB activation in RAW 264.7 cells. Life Sci. 2005, 76, 2315–2328. [Google Scholar] [CrossRef] [PubMed]
  4. Choi, J.H.; Hwang, Y.P.; Kim, H.G.; Khanal, T.; Do, M.T.; Jin, S.W.; Han, H.J.; Lee, H.S.; Lee, Y.C.; Chung, Y.C.; et al. Saponins from the roots of Platycodon grandiflorum suppresses TGFbeta1-induced epithelial-mesenchymal transition via repression of PI3K/Akt, ERK1/2 and Smad2/3 pathway in human lung carcinoma A549 cells. Nutr. Cancer 2014, 66, 140–151. [Google Scholar] [CrossRef] [PubMed]
  5. Kim, J.Y.; Park, K.W.; Moon, K.D.; Lee, M.K.; Choi, J.; Yee, S.T.; Shim, K.H.; Seo, K.I. Induction of apoptosis in HT-29 colon cancer cells by crude saponin from Platycodi Radix. Food Chem. Toxicol. 2008, 46, 3753–3758. [Google Scholar] [CrossRef] [PubMed]
  6. Choi, J.H.; Hwang, Y.P.; Han, E.H.; Kim, H.G.; Park, B.H.; Lee, H.S.; Park, B.K.; Lee, Y.C.; Chung, Y.C.; Jeong, H.G. Inhibition of acrolein-stimulated MUC5AC expression by Platycodon grandiflorum root-derived saponin in A549 cells. Food Chem. Toxicol. 2011, 49, 2157–2166. [Google Scholar] [CrossRef] [PubMed]
  7. Fu, X.J.; Liu, H.B.; Wang, P.; Guan, H.S. A study on the antioxidant activity and tissues selective inhibition of lipid peroxidation by saponins from the roots of Platycodon grandiflorum. Am. J. Chin. Med. 2009, 37, 967–975. [Google Scholar] [CrossRef] [PubMed]
  8. Chung, M.J.; Kim, S.H.; Park, J.W.; Lee, Y.J.; Ham, S.S. Platycodon grandiflorum root attenuates vascular endothelial cell injury by oxidized low-density lipoprotein and prevents high-fat diet-induced dyslipidemia in mice by up-regulating antioxidant proteins. Nutr. Res. 2012, 32, 365–373. [Google Scholar] [CrossRef] [PubMed]
  9. Ahn, K.S.; Hahn, B.S.; Kwack, K.; Lee, E.B.; Kim, Y.S. Platycodin D-induced apoptosis through nuclear factor-kappaB activation in immortalized keratinocytes. Eur. J. Pharmacol. 2006, 537, 1–11. [Google Scholar] [CrossRef] [PubMed]
  10. Li, T.; Chen, X.; Chen, X.; Ma, D.L.; Leung, C.H.; Lu, J.J. Platycodin D potentiates proliferation inhibition and apoptosis induction upon AKT inhibition via feedback blockade in non-small cell lung cancer cells. Sci. Rep. 2016, 6, 37997. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  11. Li, T.; Xu, W.S.; Wu, G.S.; Chen, X.P.; Wang, Y.T.; Lu, J.J. Platycodin D induces apoptosis, and inhibits adhesion, migration and invasion in HepG2 hepatocellular carcinoma cells. Asian Pac. J. Cancer Prev. 2014, 15, 1745–1749. [Google Scholar] [CrossRef] [PubMed]
  12. Li, T.; Xu, X.H.; Tang, Z.H.; Wang, Y.F.; Leung, C.H.; Ma, D.L.; Chen, X.P.; Wang, Y.T.; Chen, Y.; Lu, J.J. Platycodin D induces apoptosis and triggers ERK- and JNK-mediated autophagy in human hepatocellular carcinoma BEL-7402 cells. Acta Pharmacol. Sin. 2015, 36, 1503–1513. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Yu, J.S.; Kim, A.K. Platycodin D induces apoptosis in MCF-7 human breast cancer cells. J. Med. Food 2010, 13, 298–305. [Google Scholar] [CrossRef] [PubMed]
  14. Lee, E.J.; Kang, M.; Kim, Y.S. Platycodin D inhibits lipogenesis through AMPKalpha-PPARgamma2 in 3T3-L1 cells and modulates fat accumulation in obese mice. Planta Med. 2012, 78, 1536–1542. [Google Scholar] [PubMed]
  15. Lee, H.; Bae, S.; Kim, Y.S.; Yoon, Y. WNT/beta-catenin pathway mediates the anti-adipogenic effect of platycodin D, a natural compound found in Platycodon grandiflorum. Life Sci. 2011, 89, 388–394. [Google Scholar] [CrossRef] [PubMed]
  16. Chung, J.W.; Noh, E.J.; Zhao, H.L.; Sim, J.S.; Ha, Y.W.; Shin, E.M.; Lee, E.B.; Cheong, C.S.; Kim, Y.S. Anti-inflammatory activity of prosapogenin methyl ester of platycodin D via nuclear factor-kappaB pathway inhibition. Biol. Pharm. Bull. 2008, 31, 2114–2120. [Google Scholar] [CrossRef] [PubMed]
  17. Kim, Y.P.; Lee, E.B.; Kim, S.Y.; Li, D.; Ban, H.S.; Lim, S.S.; Shin, K.H.; Ohuchi, K. Inhibition of prostaglandin E2 production by platycodin D isolated from the root of Platycodon grandiflorum. Planta Med. 2001, 67, 362–364. [Google Scholar] [CrossRef] [PubMed]
  18. Wu, J.T.; Yang, G.W.; Qi, C.H.; Zhou, L.; Hu, J.G.; Wang, M.S. Anti-inflammatory activity of platycodin D on alcohol-induced fatty liver rats via TLR4-MYD88-NF-kappaB signal path. Afr. J. Tradit. Complement. Altern. Med. 2016, 13, 176–183. [Google Scholar] [CrossRef] [PubMed]
  19. Ryu, J.; Lee, H.J.; Park, S.H.; Kim, J.; Lee, D.; Lee, S.K.; Kim, Y.S.; Hong, J.H.; Seok, J.H.; Lee, C.J. Effects of the root of Platycodon grandiflorum on airway mucin hypersecretion in vivo and platycodin D(3) and deapi-platycodin on production and secretion of airway mucin in vitro. Phytomedicine 2014, 21, 529–533. [Google Scholar] [CrossRef] [PubMed]
  20. Shin, C.Y.; Lee, W.J.; Lee, E.B.; Choi, E.Y.; Ko, K.H. Platycodin D and D3 increase airway mucin release in vivo and in vitro in rats and hamsters. Planta Med. 2002, 68, 221–225. [Google Scholar] [CrossRef] [PubMed]
  21. Li, W.; Liu, Y.; Wang, Z.; Han, Y.; Tian, Y.H.; Zhang, G.S.; Sun, Y.S.; Wang, Y.P. Platycodin D isolated from the aerial parts of Platycodon grandiflorum protects alcohol-induced liver injury in mice. Food Funct. 2015, 6, 1418–1427. [Google Scholar] [CrossRef] [PubMed]
  22. Xie, Y.; He, S.W.; Sun, H.X.; Li, D. Platycodin D2 improves specific cellular and humoral responses to hepatitis B surface antigen in mice. Chem. Biodivers. 2010, 7, 178–185. [Google Scholar] [CrossRef] [PubMed]
  23. Goh, K.I.; Cusick, M.E.; Valle, D.; Childs, B.; Vidal, M.; Barabasi, A.L. The human disease network. Proc. Natl. Acad. Sci. USA 2007, 104, 8685–8690. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Hopkins, A.L. Network pharmacology: The next paradigm in drug discovery. Nat. Chem. Biol. 2008, 4, 682–690. [Google Scholar] [CrossRef] [PubMed]
  25. Park, S.Y.; Park, J.H.; Kim, H.S.; Lee, C.Y.; Lee, H.J.; Kang, K.S.; Kim, C.E. Systems-level mechanisms of action of Panax ginseng: A network pharmacological approach. J. Ginseng Res. 2018, 42, 98–106. [Google Scholar] [CrossRef] [PubMed]
  26. Tao, W.; Xu, X.; Wang, X.; Li, B.; Wang, Y.; Li, Y.; Yang, L. Network pharmacology-based prediction of the active ingredients and potential targets of Chinese herbal Radix Curcumae formula for application to cardiovascular disease. J. Ethnopharmacol. 2013, 145, 1–10. [Google Scholar] [CrossRef] [PubMed]
  27. Liang, X.; Li, H.; Li, S. A novel network pharmacology approach to analyse traditional herbal formulae: The Liu-Wei-Di-Huang pill as a case study. Mol. Biosyst. 2014, 10, 1014–1022. [Google Scholar] [CrossRef] [PubMed]
  28. Zhang, B.; Wang, X.; Li, S. An Integrative Platform of TCM Network Pharmacology and Its Application on a Herbal Formula, Qing-Luo-Yin. Evid. Based Complement. Alternat. Med. 2013, 2013, 456747. [Google Scholar] [CrossRef] [PubMed]
  29. Li, X.; Wu, L.; Liu, W.; Jin, Y.; Chen, Q.; Wang, L.; Fan, X.; Li, Z.; Cheng, Y. A network pharmacology study of Chinese medicine QiShenYiQi to reveal its underlying multi-compound, multi-target, multi-pathway mode of action. PLoS ONE 2014, 9, e95004. [Google Scholar] [CrossRef] [PubMed]
  30. Ru, J.; Li, P.; Wang, J.; Zhou, W.; Li, B.; Huang, C.; Li, P.; Guo, Z.; Tao, W.; Yang, Y.; et al. TCMSP: A database of systems pharmacology for drug discovery from herbal medicines. J. Cheminform. 2014, 6, 13. [Google Scholar] [CrossRef] [PubMed]
  31. Mi, H.; Huang, X.; Muruganujan, A.; Tang, H.; Mills, C.; Kang, D.; Thomas, P.D. PANTHER version 11: Expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements. Nucleic Acids Res. 2017, 45, D183–D189. [Google Scholar] [CrossRef] [PubMed]
  32. Mi, H.; Muruganujan, A.; Casagrande, J.T.; Thomas, P.D. Large-scale gene function analysis with the PANTHER classification system. Nat. Protoc. 2013, 8, 1551–1566. [Google Scholar] [CrossRef] [PubMed]
  33. Chen, E.Y.; Tan, C.M.; Kou, Y.; Duan, Q.; Wang, Z.; Meirelles, G.V.; Clark, N.R.; Ma’ayan, A. Enrichr: Interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinform. 2013, 14, 128. [Google Scholar] [CrossRef] [PubMed]
  34. Kuleshov, M.V.; Jones, M.R.; Rouillard, A.D.; Fernandez, N.F.; Duan, Q.; Wang, Z.; Koplev, S.; Jenkins, S.L.; Jagodnik, K.M.; Lachmann, A.; et al. Enrichr: A comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016, 44, W90–W97. [Google Scholar] [CrossRef] [PubMed]
  35. Schonlau, M. Visualizing non-hierarchical and hierarchical cluster analyses with clustergrams. Comput. Stat. 2004, 19, 95–111. [Google Scholar] [CrossRef]
  36. Zhou, W.; Wang, J.; Wu, Z.; Huang, C.; Lu, A.; Wang, Y. Systems pharmacology exploration of botanic drug pairs reveals the mechanism for treating different diseases. Sci. Rep. 2016, 6, 36985. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  37. Xu, X.; Zhang, W.; Huang, C.; Li, Y.; Yu, H.; Wang, Y.; Duan, J.; Ling, Y. A novel chemometric method for the prediction of human oral bioavailability. Int. J. Mol. Sci. 2012, 13, 6964–6982. [Google Scholar] [CrossRef] [PubMed]
  38. Tian, S.; Wang, J.; Li, Y.; Li, D.; Xu, L.; Hou, T. The application of in silico drug-likeness predictions in pharmaceutical research. Adv. Drug Deliv. Rev. 2015, 86, 2–10. [Google Scholar] [CrossRef] [PubMed]
  39. Shim, H.Y.; Park, J.H.; Paik, H.D.; Nah, S.Y.; Kim, D.S.; Han, Y.S. Acacetin-induced apoptosis of human breast cancer MCF-7 cells involves caspase cascade, mitochondria-mediated death signaling and SAPK/JNK1/2-c-Jun activation. Mol. Cells 2007, 24, 95–104. [Google Scholar] [PubMed]
  40. Hsu, Y.L.; Kuo, P.L.; Liu, C.F.; Lin, C.C. Acacetin-induced cell cycle arrest and apoptosis in human non-small cell lung cancer A549 cells. Cancer Lett. 2004, 212, 53–60. [Google Scholar] [CrossRef] [PubMed]
  41. Hsu, Y.L.; Kuo, P.L.; Lin, C.C. Acacetin inhibits the proliferation of Hep G2 by blocking cell cycle progression and inducing apoptosis. Biochem. Pharmacol. 2004, 67, 823–829. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Shen, K.H.; Hung, S.H.; Yin, L.T.; Huang, C.S.; Chao, C.H.; Liu, C.L.; Shih, Y.W. Acacetin, a flavonoid, inhibits the invasion and migration of human prostate cancer DU145 cells via inactivation of the p38 MAPK signaling pathway. Mol. Cell. Biochem. 2010, 333, 279–291. [Google Scholar] [CrossRef] [PubMed]
  43. Dok-Go, H.; Lee, K.H.; Kim, H.J.; Lee, E.H.; Lee, J.; Song, Y.S.; Lee, Y.H.; Jin, C.; Lee, Y.S.; Cho, J. Neuroprotective effects of antioxidative flavonoids, quercetin, (+)-dihydroquercetin and quercetin 3-methyl ether, isolated from Opuntia ficus-indica var. saboten. Brain Res. 2003, 965, 130–136. [Google Scholar] [CrossRef]
  44. Teselkin, Y.O.; Babenkova, I.V.; Kolhir, V.K.; Baginskaya, A.I.; Tjukavkina, N.A.; Kolesnik, Y.A.; Selivanova, I.A.; Eichholz, A.A. Dihydroquercetin as a means of antioxidative defence in rats with tetrachloromethane hepatitis. Phytother. Res. 2000, 14, 160–162. [Google Scholar] [CrossRef]
  45. Jeong, C.-H.; Choi, G.N.; Kim, J.H.; Kwak, J.H.; Kim, D.O.; Kim, Y.J.; Heo, H.J. Antioxidant activities from the aerial parts of Platycodon grandiflorum. Food Chem. 2010, 118, 278–282. [Google Scholar] [CrossRef]
  46. Park, S.W.; Cho, C.S.; Ryu, N.H.; Kim, J.H.; Kim, J.S.; Kim, J.H. Luteolin extracted from Platycodon grandiflorum protects retinal pigment epithelial cells from oxidative stress-induced caspase-3 dependent apoptosis. Biomed. Prev. Nutr. 2012, 2, 77–80. [Google Scholar] [CrossRef]
  47. Kuppusamy, U.R.; Das, N.P. Effects of flavonoids on cyclic AMP phosphodiesterase and lipid mobilization in rat adipocytes. Biochem. Pharmacol. 1992, 44, 1307–1315. [Google Scholar] [CrossRef]
  48. Park, S.W.; Cho, C.S.; Jun, H.O.; Ryu, N.H.; Kim, J.H.; Yu, Y.S.; Kim, J.S.; Kim, J.H. Anti-angiogenic effect of luteolin on retinal neovascularization via blockade of reactive oxygen species production. Investig. Ophthalmol. Vis. Sci. 2012, 53, 7718–7726. [Google Scholar] [CrossRef] [PubMed]
  49. Villasenor, I.M.; Domingo, A.P. Anticarcinogenicity potential of spinasterol isolated from squash flowers. Teratog. Carcinog. Mutagen. 2000, 20, 99–105. [Google Scholar] [CrossRef]
  50. Jeon, G.C.; Park, M.S.; Yoon, D.Y.; Shin, C.H.; Sin, H.S.; Um, S.J. Antitumor activity of spinasterol isolated from Pueraria roots. Exp. Mol. Med. 2005, 37, 111–120. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  51. Trevisan, G.; Rossato, M.F.; Walker, C.I.; Klafke, J.Z.; Rosa, F.; Oliveira, S.M.; Tonello, R.; Guerra, G.P.; Boligon, A.A.; Zanon, R.B.; et al. Identification of the plant steroid alpha-spinasterol as a novel transient receptor potential vanilloid 1 antagonist with antinociceptive properties. J. Pharmacol. Exp. Ther. 2012, 343, 258–269. [Google Scholar] [CrossRef] [PubMed]
  52. Xu, C.; Sun, G.; Yuan, G.; Wang, R.; Sun, X. Effects of platycodin D on proliferation, apoptosis and PI3K/Akt signal pathway of human glioma U251 cells. Molecules 2014, 19, 21411–21423. [Google Scholar] [CrossRef] [PubMed]
  53. Yoo, D.S.; Choi, Y.H.; Cha, M.R.; Lee, B.H.; Kim, S.-J.; Yon, G.H.; Hong, K.S.; Jang, Y.S.; Lee, H.S.; Kim, Y.S.; et al. HPLC-ELSD analysis of 18 platycosides from balloon flower roots (Platycodi Radix) sourced from various regions in Korea and geographical clustering of the cultivation areas. Food Chem. 2011, 129, 645–651. [Google Scholar] [CrossRef]
  54. Yu, H.; Chen, J.; Xu, X.; Li, Y.; Zhao, H.; Fang, Y.; Li, X.; Zhou, W.; Wang, W.; Wang, Y. A systematic prediction of multiple drug-target interactions from chemical, genomic, and pharmacological data. PLoS ONE 2012, 7, e37608. [Google Scholar] [CrossRef] [PubMed]
  55. Shannon, P.; Markiel, A.; Ozier, O.; Baliga, N.S.; Wang, J.T.; Ramage, D.; Amin, N.; Schwikowski, B.; Ideker, T. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 2003, 13, 2498–2504. [Google Scholar] [CrossRef] [PubMed]
  56. Zhang, L.; Wang, Y.; Yang, D.; Zhang, C.; Zhang, N.; Li, M.; Liu, Y. Platycodon grandiflorus–An ethnopharmacological, phytochemical and pharmacological review. J. Ethnopharmacol. 2015, 164, 147–161. [Google Scholar] [CrossRef] [PubMed]
  57. Nyakudya, E.; Jeong, J.H.; Lee, N.K.; Jeong, Y.S. Platycosides from the Roots of Platycodon grandiflorum and Their Health Benefits. Prev. Nutr. Food Sci. 2014, 19, 59–68. [Google Scholar] [CrossRef] [PubMed]
  58. Ciruelos Gil, E.M. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treat. Rev. 2014, 40, 862–871. [Google Scholar] [CrossRef] [PubMed]
  59. Edlind, M.P.; Hsieh, A.C. PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance. Asian J. Androl. 2014, 16, 378–386. [Google Scholar] [PubMed]
  60. Kargman, S.L.; O’Neill, G.P.; Vickers, P.J.; Evans, J.F.; Mancini, J.A.; Jothy, S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res. 1995, 55, 2556–2559. [Google Scholar] [PubMed]
  61. Seibert, K.; Zhang, Y.; Leahy, K.; Hauser, S.; Masferrer, J.; Perkins, W.; Lee, L.; Isakson, P. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc. Natl. Acad. Sci. USA 1994, 91, 12013–12017. [Google Scholar] [CrossRef] [PubMed]
  62. Kim, S.F.; Huri, D.A.; Snyder, S.H. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 2005, 310, 1966–1970. [Google Scholar] [CrossRef] [PubMed]
  63. Hokari, A.; Zeniya, M.; Esumi, H. Cloning and functional expression of human inducible nitric oxide synthase (NOS) cDNA from a glioblastoma cell line A-172. J. Biochem. 1994, 116, 575–581. [Google Scholar] [CrossRef] [PubMed]
  64. Kim, C.Y.; Whittington, D.A.; Chang, J.S.; Liao, J.; May, J.A.; Christianson, D.W. Structural aspects of isozyme selectivity in the binding of inhibitors to carbonic anhydrases II and IV. J. Med. Chem. 2002, 45, 888–893. [Google Scholar] [CrossRef] [PubMed]
  65. Lehenkari, P.; Hentunen, T.A.; Laitala-Leinonen, T.; Tuukkanen, J.; Vaananen, H.K. Carbonic anhydrase II plays a major role in osteoclast differentiation and bone resorption by effecting the steady state intracellular pH and Ca2+. Exp. Cell. Res. 1998, 242, 128–137. [Google Scholar] [CrossRef] [PubMed]
  66. Subramanian, A.; Tamayo, P.; Mootha, V.K.; Mukherjee, S.; Ebert, B.L.; Gillette, M.A.; Paulovich, A.; Pomeroy, S.L.; Golub, T.R.; Lander, E.S.; et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102, 15545–15550. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  67. Ogata, H.; Goto, S.; Sato, K.; Fujibuchi, W.; Bono, H.; Kanehisa, M. KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res. 1999, 27, 29–34. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  68. Shin, D.Y.; Kim, G.Y.; Li, W.; Choi, B.T.; Kim, N.D.; Kang, H.S.; Choi, Y.H. Implication of intracellular ROS formation, caspase-3 activation and Egr-1 induction in platycodon D-induced apoptosis of U937 human leukemia cells. Biomed. Pharmacother. 2009, 63, 86–94. [Google Scholar] [CrossRef] [PubMed]
  69. Yim, N.H.; Hwang, Y.H.; Liang, C.; Ma, J.Y. A platycoside-rich fraction from the root of Platycodon grandiflorum enhances cell death in A549 human lung carcinoma cells via mainly AMPK/mTOR/AKT signal-mediated autophagy induction. J. Ethnopharmacol. 2016, 194, 1060–1068. [Google Scholar] [CrossRef] [PubMed]
  70. Li, T.; Chen, X.; Dai, X.-Y.; Wei, B.; Weng, Q.-J.; Chen, X.; Ouyang, D.-F.; Yan, R.; Huang, Z.-J.; Jiang, H.-L.; et al. Novel Hsp90 inhibitor platycodin D disrupts Hsp90/Cdc37 complex and enhances the anticancer effect of mTOR inhibitor. Toxicol. Appl. Pharmacol. 2017, 330, 65–73. [Google Scholar] [CrossRef] [PubMed]
  71. Choi, C.Y.; Kim, J.Y.; Kim, Y.S.; Chung, Y.C.; Seo, J.K.; Jeong, H.G. Aqueous extract isolated from Platycodon grandiflorum elicits the release of nitric oxide and tumor necrosis factor-α from murine macrophages. Int. Immunopharmacol. 2001, 1, 1141–1151. [Google Scholar] [CrossRef]
  72. Kim, J.Y.; Kim, D.H.; Kim, H.G.; Song, G.-Y.; Chung, Y.C.; Roh, S.H.; Jeong, H.G. Inhibition of tumor necrosis factor-α-induced expression of adhesion molecules in human endothelial cells by the saponins derived from roots of Platycodon grandiflorum. Toxicol. Appl. Pharmacol. 2006, 210, 150–156. [Google Scholar] [CrossRef] [PubMed]
  73. Klein, T.E.; Chang, J.T.; Cho, M.K.; Easton, K.L.; Fergerson, R.; Hewett, M.; Lin, Z.; Liu, Y.; Liu, S.; Oliver, D.E.; et al. Integrating genotype and phenotype information: An overview of the PharmGKB project. Pharmacogenomics J. 2001, 1, 167–170. [Google Scholar] [CrossRef] [PubMed]
  74. Yang, H.; Qin, C.; Li, Y.H.; Tao, L.; Zhou, J.; Yu, C.Y.; Xu, F.; Chen, Z.; Zhu, F.; Chen, Y.Z. Therapeutic target database update 2016: Enriched resource for bench to clinical drug target and targeted pathway information. Nucleic Acids Res. 2016, 44, D1069–D1074. [Google Scholar] [CrossRef] [PubMed]
  75. Tang, Z.-H.; Li, T.; Gao, H.-W.; Sun, W.; Chen, X.-P.; Wang, Y.-T.; Lu, J.-J. Platycodin D from Platycodonis Radix enhances the anti-proliferative effects of doxorubicin on breast cancer MCF-7 and MDA-MB-231 cells. Chin. Med. 2014, 9, 16. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  76. Hwang, Y.P.; Choi, J.H.; Kim, H.G.; Lee, H.-S.; Chung, Y.C.; Jeong, H.G. Saponins from Platycodon grandiflorum inhibit hepatic lipogenesis through induction of SIRT1 and activation of AMP-activated protein kinase in high-glucose-induced HepG2 cells. Food Chem. 2013, 140, 115–123. [Google Scholar] [CrossRef] [PubMed]
  77. Kim, J.-Y.; Moon, K.-D.; Seo, K.-I.; Park, K.-W.; Choi, M.-S.; Do, G.-M.; Jeong, Y.-K.; Cho, Y.-S.; Lee, M.-K. Supplementation of SK1 from Platycodi Radix Ameliorates Obesity and Glucose Intolerance in Mice Fed a High-Fat Diet. J. Med. Food 2009, 12, 629–636. [Google Scholar] [CrossRef] [PubMed]
  78. Son, I.; Park, Y.; Lee, S.; Yang, H.; Moon, H.-I. Neuroprotective Activity of Triterpenoid Saponins from Platycodi radix Against Glutamate-induced Toxicity in Primary Cultured Rat Cortical Cells. Molecules 2007, 12, 1147. [Google Scholar] [CrossRef] [PubMed]
  79. Han, S.B.; Park, S.H.; Lee, K.H.; Lee, C.W.; Lee, S.H.; Kim, H.C.; Kim, Y.S.; Lee, H.S.; Kim, H.M. Polysaccharide isolated from the radix of Platycodon grandiflorum selectively activates B cells and macrophages but not T cells. Int. Immunopharmacol. 2001, 1, 1969–1978. [Google Scholar] [CrossRef]
  80. Ouyang, K.; Chen, L.; Sun, H.; Du, J.; Shi, M. Screening and appraisal for immunological adjuvant-active fractions from Platycodon grandiflorum total saponins. Immunopharmacol. Immunotoxicol. 2012, 34, 126–134. [Google Scholar] [CrossRef] [PubMed]
  81. Guo, Y.; Nie, Q.; MacLean, A.L.; Li, Y.; Lei, J.; Li, S. Multiscale Modeling of Inflammation-Induced Tumorigenesis Reveals Competing Oncogenic and Oncoprotective Roles for Inflammation. Cancer Res. 2017, 77, 6429–6441. [Google Scholar] [CrossRef] [PubMed]
  82. Lv, C.; Wu, X.; Wang, X.; Su, J.; Zeng, H.; Zhao, J.; Lin, S.; Liu, R.; Li, H.; Li, X.; et al. The gene expression profiles in response to 102 traditional Chinese medicine (TCM) components: A general template for research on TCMs. Sci. Rep. 2017, 7, 352. [Google Scholar] [CrossRef] [PubMed]
Molecules 23 02841 g001 550
Figure 1. Framework of network pharmacological analysis of Platycodon grandiflorum (PG); TCMSP: Traditional Chinese Medicine Systems Pharmacology database; OB: oral bioavailability; DL: drug-likeness.
Figure 1. Framework of network pharmacological analysis of Platycodon grandiflorum (PG); TCMSP: Traditional Chinese Medicine Systems Pharmacology database; OB: oral bioavailability; DL: drug-likeness.
Molecules 23 02841 g001
Molecules 23 02841 g002 550
Figure 2. Chemical structures of PG compounds. (a) Four components of PG were selected from the TCMSP database with threshold values of 30 and 0.18 for OB and DL, respectively. (b) Platycodin D is a major active component of PG.
Figure 2. Chemical structures of PG compounds. (a) Four components of PG were selected from the TCMSP database with threshold values of 30 and 0.18 for OB and DL, respectively. (b) Platycodin D is a major active component of PG.
Molecules 23 02841 g002
Molecules 23 02841 g003 550
Figure 3. Compound–target–disease (CTD) network of PG. The red circles represent compounds, the purple circles represent targets, and the orange circles represent diseases. The compounds, targets, and diseases of each network are sorted in descending order from the bottom of the figure in a circular layout, on the basis of the number of degrees. The size of the target and disease nodes reflects the number of degrees. The node was removed when the number of degrees of the target and disease nodes was <3. The orange box represents the top five targets and diseases in terms of degrees.
Figure 3. Compound–target–disease (CTD) network of PG. The red circles represent compounds, the purple circles represent targets, and the orange circles represent diseases. The compounds, targets, and diseases of each network are sorted in descending order from the bottom of the figure in a circular layout, on the basis of the number of degrees. The size of the target and disease nodes reflects the number of degrees. The node was removed when the number of degrees of the target and disease nodes was <3. The orange box represents the top five targets and diseases in terms of degrees.
Molecules 23 02841 g003
Molecules 23 02841 g004 550
Figure 4. Biological processes related to targets of PG. Targets were assigned to biological processes using “Panther GO-slim Biological Process”. Hits mean the number of assigned targets to the corresponding biological processes. The proportion of each biological process is color-coded in the pie chart.
Figure 4. Biological processes related to targets of PG. Targets were assigned to biological processes using “Panther GO-slim Biological Process”. Hits mean the number of assigned targets to the corresponding biological processes. The proportion of each biological process is color-coded in the pie chart.
Molecules 23 02841 g004
Molecules 23 02841 g005 550
Figure 5. Pathway analysis using the Kyoto Encyclopedia of Genes and Genomes (KEGG) 2016 library. Analysis was performed on the “Enrichr” platform (http://amp.pharm.mssm.edu/Enrichr/). The 112 targets of PG were used to obtain the results. (a) The top 10 enriched pathway terms are displayed in a bar graph. They are ranked by a combined score calculated by p-value and z-score. The length of the bar and the brightness of its color represent the significance of the specific pathway. (b) The top 10 enriched pathway terms are displayed as a network. Each node represents a pathway, and each edge represents the gene content similarity among the pathways.
Figure 5. Pathway analysis using the Kyoto Encyclopedia of Genes and Genomes (KEGG) 2016 library. Analysis was performed on the “Enrichr” platform (http://amp.pharm.mssm.edu/Enrichr/). The 112 targets of PG were used to obtain the results. (a) The top 10 enriched pathway terms are displayed in a bar graph. They are ranked by a combined score calculated by p-value and z-score. The length of the bar and the brightness of its color represent the significance of the specific pathway. (b) The top 10 enriched pathway terms are displayed as a network. Each node represents a pathway, and each edge represents the gene content similarity among the pathways.
Molecules 23 02841 g005
Molecules 23 02841 g006 550
Figure 6. Clustergram of pathways. Rows and columns represent the pathways and input genes, respectively. The enriched terms in the rows of the heat map are clustered by the similarity of the gene contents. The input genes in the column are sorted in descending order of the sum of the columns from left to right. The colors of the boxes represent each cluster.
Figure 6. Clustergram of pathways. Rows and columns represent the pathways and input genes, respectively. The enriched terms in the rows of the heat map are clustered by the similarity of the gene contents. The input genes in the column are sorted in descending order of the sum of the columns from left to right. The colors of the boxes represent each cluster.
Molecules 23 02841 g006
Molecules 23 02841 g007 550
Figure 7. Degree matrices of the related diseases. Each row represents the major diseases of the CTD network, and each column represents the 10 thresholds of OB and DL. (a) The matrix shows the absolute degree of each disease. Only diseases with an average degree of 3 or higher are displayed. The color bar indicates the absolute degree of diseases. (b) The matrix represents the relative degree. Only the top 50% of diseases indicated by total herbs’ degrees are selected. The color bar represents the relative degree of diseases.
Figure 7. Degree matrices of the related diseases. Each row represents the major diseases of the CTD network, and each column represents the 10 thresholds of OB and DL. (a) The matrix shows the absolute degree of each disease. Only diseases with an average degree of 3 or higher are displayed. The color bar indicates the absolute degree of diseases. (b) The matrix represents the relative degree. Only the top 50% of diseases indicated by total herbs’ degrees are selected. The color bar represents the relative degree of diseases.
Molecules 23 02841 g007
Table
Table 1. Top 10 targets in the compound–target (CT) network and pharmacological activity of each target.
Table 1. Top 10 targets in the compound–target (CT) network and pharmacological activity of each target.
Gene NameProtein NameTarget DegreesPharmacological Activities in Uniprot
PRSS1Trypsin-117-
DPP4Dipeptidyl peptidase IV16Immune activitiesAnti-diabetic activitiesAnti-microbial activities
ESR1Estrogen receptor12Anti-inflammatory activitiesAnti-cancer activitiesAnti-tumor activities
PTGS2Prostaglandin G/H synthase 212Anti-inflammatory activitiesAnti-cancer activitiesAnti-tumor activities
PTGS1Prostaglandin G/H synthase 112Anti-inflammatory activities
ADH1CAlcohol dehydrogenase 1C12-
ARAndrogen receptor10Anti-cancer activities
NOS2Nitric oxide synthase, inducible9Anti-tumor activitiesAnti-microbial activitiesAnti-inflammatory activities
CA2Carbonic anhydrase II9Anti-cancer activities
F2Prothrombin9Cardiovascular activities
Table
Table 2. Cluster of the enriched pathway. PI3K—phosphatidylinositol 3-kinase; HIF-1—hypoxia-inducible factor 1; AGE—advanced glycation end products; RAGE—receptor for AGE; TNF—tumor necrosis factor.
Table 2. Cluster of the enriched pathway. PI3K—phosphatidylinositol 3-kinase; HIF-1—hypoxia-inducible factor 1; AGE—advanced glycation end products; RAGE—receptor for AGE; TNF—tumor necrosis factor.
Cluster No.Enriched Pathway
Cluster 1Pathways in cancer
Cluster 2PI3K signaling pathway
Cluster 3HIF-1 signaling pathway
Cluster 4Proteoglycans in cancer
Cluster 5Estrogen signaling pathway
Cluster 6AGE/RAGE signaling pathway in diabetic complications, apoptosis, T-cell receptor signaling pathway, Chagas disease (American trypanosomiasis), TNF signaling pathway, influenza A
Cluster 7Insulin signaling pathway, thyroid hormone signaling pathway, non-alcoholic fatty liver disease (NAFLD), insulin resistance
Cluster 8Prostate cancer, bladder cancer, pancreatic cancer, glioma, melanoma
Cluster 9Measles, Epstein–Barr virus infection, small-cell lung cancer, hepatitis B, viral carcinogenesis
Table
Table 3. The potential target diseases based on the absolute degree matrix of Platycodon grandiflorum.
Table 3. The potential target diseases based on the absolute degree matrix of Platycodon grandiflorum.
Disease NameDegree (From the 1st Level Threshold)Disease NameDegree (From the 1st Level Threshold)
Cancer, unspecific11Alcoholism3
Breast cancer9Bladder cancer3
Pancreatic cancer7Neurodegenerative diseases3
Alzheimer’s disease7Brain injury3
Prostate cancer7Schizophrenia3
Inflammation5Hepatocellular carcinoma3
Cardiovascular disease, unspecified5Multiple sclerosis3
Non-small-cell lung cancer5Chronic inflammatory diseases3
Non-insulin-dependent diabetes mellitus5Diabetes mellitus3
Solid tumors5Osteoarthritis3
Renal cell carcinoma4Anxiety disorder, unspecified3
Obesity4Rheumatoid arthritis, unspecified3
Multiple myeloma4Crohn’s disease, unspecified3
Lung cancer4Asthma3
Table
Table 4. The potential target diseases based on the relative degree matrix of Platycodon grandiflorum. HCV—hepatitis C virus.
Table 4. The potential target diseases based on the relative degree matrix of Platycodon grandiflorum. HCV—hepatitis C virus.
Disease NameRelative Degree (From the 1st Level Threshold)Disease NameRelative Degree (From the 1st Level Threshold)
Hepatocellular carcinoma0.82Pancreatic cancer0.53
Gastric cancer0.81Solid tumor0.53
Prostate cancer (metastatic)0.80HCV infection0.52
Small-cell lung cancer0.79Head and neck tumors0.52
Renal cell carcinoma0.75Lymphangiomatosis0.52
Squamous cell carcinoma0.66Non-small cell lung cancer0.51
Endometrial carcinoma0.62Prostate cancer0.49
Metastatic osteosarcoma in the lung0.62Colorectal cancer0.48
Leukemia, unspecified0.61Hormone-refractory prostate cancer0.47
Tumors0.59Kaposi’s sarcoma0.47
Breast cancer0.56Lung cancer0.47
Mesothelioma0.55Obesity0.45
Glioblastoma multiforme0.54Solid tumors0.34
Insulin-dependent diabetes mellitus0.53

Share and Cite

MDPI and ACS Style

Park, M.; Park, S.-Y.; Lee, H.-J.; Kim, C.-E. A Systems-Level Analysis of Mechanisms of Platycodon grandiflorum Based on A Network Pharmacological Approach. Molecules 2018, 23, 2841. https://doi.org/10.3390/molecules23112841

AMA Style

Park M, Park S-Y, Lee H-J, Kim C-E. A Systems-Level Analysis of Mechanisms of Platycodon grandiflorum Based on A Network Pharmacological Approach. Molecules. 2018; 23(11):2841. https://doi.org/10.3390/molecules23112841

Chicago/Turabian Style

Park, Musun, Sa-Yoon Park, Hae-Jeung Lee, and Chang-Eop Kim. 2018. "A Systems-Level Analysis of Mechanisms of Platycodon grandiflorum Based on A Network Pharmacological Approach" Molecules 23, no. 11: 2841. https://doi.org/10.3390/molecules23112841

Article Metrics

Back to TopTop